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Abstract
Objective: Insulin resistance induces hyperinsulinemic compensation, which in turn maintains almost a constant disposition
index. However, the signal that gives rise to the hyperinsulinemic compensation for insulin resistance remains unknown.
Methods: In a dog model of obesity we examined the possibility that potential early-week changes in plasma FFA, glucose,
or both could be part of a cascade of signals that lead to compensatory hyperinsulinemia induced by insulin resistance.
Results: Hypercaloric high fat feeding in dogs resulted in modest weight gain, and an increase in adipose tissue with no
change in the non-adipose tissue size. To compensate for the drop in insulin sensitivity, there was a significant rise in plasma
insulin, which can be attributed in part to a decrease in the metabolic clearance rate of insulin and increased insulin
secretion. In this study we observed complete compensation for high fat diet induced insulin resistance as measured by the
disposition index. The compensatory hyperinsulinemia was coupled with significant changes in plasma FFAs and no change
in plasma glucose.
Conclusions: We postulate that early in the development of diet induced insulin resistance, a change in plasma FFAs may
directly, through signaling at the level of b-cell, or indirectly, by decreasing hepatic insulin clearance, result in the observed
hyperinsulinemic compensation.
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Introduction
In 1981 our group pioneered the concept that there is a specific
relationship between insulin secretion and insulin action that can
be described by a rectangular hyperbola [1]. According to the
‘‘hyperbolic law’’ [2], the product of insulin secretion and insulin
sensitivity approximates a constant, termed disposition index
(DI). The hyperbolic relationship suggests that an environmental
change in insulin sensitivity (i.e. obesity, exercise) will be well
compensated by a change in insulin secretion. For example, the
onset of obesity has been shown to be associated with insulin
resistance. [3,4]. Furthermore, it was shown that obesity is
correlated with fasting hyperinsulinemia [5].
Even with the abundance of evidence documenting hyperinsu-
linemic compensation for insulin resistance in rodent, dog and
human studies, the precise mechanism by which a normal organism
detects insulin resistance and compensates with hyperinsulinemia
remains unknown. Terauchi et al. and colleagues showed that
hyperinsulinemic compensation was absent in glucose kinase (Gck)
deficient mice with FFA plasma levels matched to high fat fed
controls [6]. Given that glucose kinase is an important enzyme in
the pancreas glucose sensing pathway, Weir and colleagues
concluded that glucose is the dominant signal in hyperinsulinemic
compensation for insulin resistance [7]. Despite the plethora of
studies showing the presence of normoglycemia in the hyperinsu-
linemic state [8,9], Weir contends that the change in insulin
sensitivity and the accompanying change in insulin secretion can be
explained by glucose signaling [7]. Nevertheless, Steil and
colleagues showed that chronic oversupply of both glucose and
FFAs inthe rodentmodel leadsto a robustincrease inbeta-cell mass
accompanied by hyperinsulinemia [10]. Interestingly, Carpentier
andcolleagueshaveshown that prolonged elevation ofplasmaFFAs
leads to impaired secretion of insulin in nondiabetic obese humans
[11]. Thus, these data provide evidence that perhaps the early
change in plasma glucose or FFA produces chronic changes in
insulin secretion. Therefore, it can be argued that due to the
importance of nutrient homeostasis, an early transient change in
plasma glucose or FFA that is quickly normalized might induce a
robust and prolonged insulin secretion response.
Our group has reported that after six weeks of hypercaloric
high-fat diet, dogs develop insulin resistance that is countered with
hyperinsulinemic compensation [12]. After six weeks of fat
feeding, there was no measurable change in fasting glucose, or
fasting FFAs. However, there was a significant rise in nocturnal FFA
plasma levels and no change in nocturnal plasma glucose after six
weeks of high-fat feeding in the face of hepatic insulin resistance.
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and the significant rise in nocturnal plasma FFAs, the possibility
arose that the change in nocturnal FFAs could be a signal for
hyperinsulinemic compensation. Thus, our study was in accor-
dance with previous findings by Morgan and colleagues that
showed the diurnal pattern of plasma FFAs [13]. However, our
previous study did not exclude the possibility that an earlier-week
rise in fasting glucose, FFAs or both could potentially augment
insulin secretion. Thus, preliminary data suggests that glucose
might not be the signal for hyperinsulinemic compensation. In
contrast, nocturnal plasma FFAs emerge as a possible sole signal
for high fat diet-induced hyperinsulinemic compensation.
We felt that there was a need to examine longitudinally the role
of early-week changes in glucose, FFA or both as potential signals
for compensatory hyperinsulinemia associated with high-fat diet
induced insulin resistance. We hypothesized that the onset of
insulin resistance would be closely followed by a change in plasma
FFAs, and may result in changes of plasma glucose. The change in
plasma FFAs alone or in conjunction with the change in plasma
glucose could signal an increase in insulin secretion and
consequent hyperinsulinemic compensation. Thus, we expected
DI to remain constant throughout the six weeks study period.
Methods
Ethics Statement
All experimental protocols were approved by the USC
Institutional Animal Care and Use Committee.
Experimental Design
Prior to initiation of the hypercaloric high fat diet (baseline
studies), every animal was subjected to a FSIGT protocol to assess
SI, AIRg, Sg, and DI using MINMOD, the computer program for
estimating the parameters of Bergman’s Minimal Model [14]. The
baseline FSIGTs were followed by evening and nighttime
sampling of plasma glucose and FFAs during two time periods
(6–8 PM, 2–4 AM) during the course of one day, a week before
initiating hypercaloric high fat feeding. Also, we conducted
baseline MRIs to assess body composition. Once the baseline
studies were completed the hypercaloric high fat diet was initiated
for a period of six weeks. For each animal we performed bi-weekly
FSIGTs throughout the fat feeding regimen for a total of six weeks.
At week six, we once again measured plasma glucose and FFA
during the two time periods mentioned above. In addition, a
second set of MRI’s was conducted at the end of the study to assess
changes in body composition.
Animals
All experiments were conducted on male mongrel dogs in the
conscious relaxed state. Animals were housed under controlled
kennel conditions (12-h light/dark cycle) in the University of
Southern California (USC) Medical School Vivarium. Animals
were accepted into the study following physical examination and a
comprehensive blood panel. Dogs were used for experiments only
if judged to be in good health as determined by visual observation,
body temperature, and hematocrit.
Diet
Dogs were fed a weight-maintaining standard diet of one can of
Hill’s Prescription Diet (415 g, 10% carbohydrate, 9% protein, 8%
fat, 0.3% fiber, and 73% moisture [Hill’s Pet Nutrition, Topeka,
KS]) and 825 g dry chow (40% carbohydrate, 26% protein, 14%
fat, and 3% fiber [mixture of Laboratory High Density Canine Diet
and Prolab Canine 2000, Richmond, IN]) for a period of 2–3 weeks
priortoconductinganyexperimentstomonitorweightstabilization.
This standard diet consisted of 3880 kcal/day: 38% from
carbohydrates, 26% from protein and 36% from fat. Following
weight stabilization, dogs were switched to hypercaloric, high fat
diet for a period of 6 weeks in which the standard diet was
supplemented with 6 g per kg of pre-diet body weight cooked bacon
grease supplied by the Keck School of Medicine cafeteria. This
hypercaloric, high fat diet consisted of 5392 kcal/day: 27%
carbohydrates, 19% protein and 53% fat. All animals were
presented with the food at approximately 9 AM each morning
and the food was withdrawn at 12 PM. On days when experiments
were conducted, the food was presented to the dogs upon their
return to the vivarium and it was withdrawn after 3 hours.
FSIGT
The FSIGTs were performed as previously described [15].
Glucose and insulin doses were determined based on the animal’s
body weight the day before the experiment. Animals were
familiarized with the Pavlov sling at least one week before the
first FSIGT. At approximately 7 AM on the day of the FSIGT,
animals were brought into the laboratory and placed in the Pavlov
sling. A 19-gauge angiocatheter was placed in a peripheral vein
and secured. Approximately 20 min later the first fasting sample
was taken. After three fasting samples (220, 210, and 21 min),
0.3 g/kg of glucose (50% dextrose, 454 mg/ml) was injected into
the peripheral vein (t=0). Subsequently, insulin was injected at
t=20 min (0.03 U/kg porcine insulin; Eli Lilly and Company,
Indianapolis, IN, USA). Additional blood samples at t=2, 3, 4, 5,
6, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 30, 40, 50, 60, 70, 80, 90,
100, 110, 120, 140, 160, and 180 min were taken for assay of
glucose, FFA, C-peptide and insulin.
Plasma Glucose and FFAs
Fasting values were defined as the average of the three samples
(220, 210, and 21 min) before the glucose bolus. In addition to the
fasting samples we obtained 10 additional samples of plasma glucose
and FFAs measured within two time intervals (6–8 PM, 2–4 AM).
Blood Sampling
Samples for determination of glucose and insulin samples were
placed into 1.7 ml chilled tubes coated with lithium fluoride and
heparin containing 50 ml EDTA. FFA samples were taken in 1.7 ml
tubes with 25 mlE D T Aa n d5 0 ml paraoxon to inhibit lipase
activity. C-peptide was collected into tubes containing 25 ml EDTA,
50 ml Trasylol. All samples were immediately centrifuged, and
plasma separated. All samples were stored at 280uC until analysis.
Assays
Glucose was measured in duplicate with a YSI 2300
autoanalyzer (Yellow Springs Instruments; Yellow Springs, OH,
USA). Free fatty acids (NEFA C, Wako Pure Chemical Industries;
Richmond, VA, USA) were measured using colorimetric methods
in commercially available kits. Insulin was measured by an ELISA
originally developed for human serum or plasma (Linco Research,
St. Charles, MO, USA) and adapted for dog plasma in our
laboratory. The method is based on the two murine monoclonal
antibodies that bind to different epitopes of insulin, but do not
bind to proinsulin. C-Peptides are measured using radioimmuno-
assay kits (Millipore Corporation, Billerica, MA).
Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) scans were performed on
the dogs as previously described [16]. Thirty 1-cm axial abdominal
Consistency of the Disposition Index
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e18134images (T1 slices; TR 500 TE:14) were obtained using a General
Electric 1.5 Tesla Horizon (v5.7 software) magnet. Of the 30
images obtained, approximately 20 were used for analysis of total
trunk body fat, depending on the relative torso length of the
animal. Images were analyzed using Scion Image (Windows 2000
Version Beta 4.0.2; Scion Corporation, Frederick, MD, USA),
which quantifies fat tissue (pixel value 121–254) and other tissue
(20–120) in each slice. Fat volume was calculated by dividing the
number of pixels counted as fat by the ratio of the total number of
pixels (2566256) and known area (34.9 cm634.9 cm) for a 1-cm
image. Total trunk fat and tissue was estimated as the integrated
fat or tissue across all 20 slices. Percent fat was calculated as the
total trunk fat divided by the total trunk tissue. Omental fat is
defined as fat within the peritoneal cavity in an 11-cm region of
the thorax, using the slice at the level where the left renal artery
branches from the abdominal aorta as a midpoint landmark.
Percent omental fat was calculated as the omental fat divided by
the total tissue area in these same slices.
Calculations
Minimal model parameters. Insulin Sensitivity (SI) and
glucose effectiveness (Sg) was calculated by fitting the glucose
profiles from the FSIGTs using Minmod Millennium (Version
6.02, 2004), MINMOD Inc., Los Angeles, CA. AIRg was
calculated as the AUC of the insulin concentration above the
average of the basal value, from 0 to 10 min after the glucose
injection. DI, which represents a measure of insulin responsiveness
corrected for changes in SI, was calculated as the product of the
average SI and AIRg from each experiment.
Glucose Tolerance (Kg). Glucose tolerance was assessed by
the Kg parameter, which is calculated as the slope of the natural
log of the glucose concentration vs. time from 8 to 19 min after the
glucose bolus.
Metabolic Clearance Rate of Insulin (MCR). The MCR
of insulin (ml/kg/min) was calculated as the ratio of the amount of
insulin (pmol/l) to the area under the fitted decay curve of insulin
profile from t=20 minutes (time of insulin bolus) to 60 minutes
[17]. The fit of the model required to estimate the AUC and the
calculation of MCR was obtained using WinSAAM, Mathematical
Modeling Program, Kennett Square, PA.
Statistical Analysis
All experimental data are expressed as means 6 SE. General
estimation equation with interaction expansion were used to
compare all longitudinal data before and after fat feeding. Paired
Student’s t tests was used to identify the changes in MRI
determined total tissue, total fat tissue, visceral adipose tissue
(VAT), subcutaneous adipose tissue (SAT), and non-fat tissue.
Spearman rank correlation coefficient was used to calculate the
correlations between two indexes. Most of statistical calculations
were conducted using STATA, statistical package program, Stata
Corp., State College, TX. T-tests was performed using Excel
2003, Microsoft, Redmond, WA.
Results
Body composition
Mean body weight increased by 1.8360.25 kg (P,0.001) at
week 2 from 28.4361.62 kg and remained elevated until the end
of the study (Week 6: 1.8960.25 kg, P,0.001, Fig. 1A). Weight
gain was coupled with a 23.562.5 % (P=0.02) increase in total
trunk body fat tissue volume. This increase in body fat tissue was
associated with both an increase in both visceral adipose tissue
volume (VAT, 14.461.4 %, P=0.06, Fig. 1B) and subcutaneous
adipose tissue volume (SAT, 36.761.3 %, P=0.02). Additionally,
this increase in volume of adipose tissue was associated with an
increase in adipose fat mass (VAT,20.363.2 %, P=0.03; SAT,
43.865.6 %, P,0.01) There was no change in the volume or mass
of non-fat tissue (data not shown).
Fasting glucose and FFAs
Fasting plasma insulin increased by week 2 (week 0: 8.861.8 vs.
week 2: 13.162 mU/ml, P=0.038, Fig. 2A) and this increase was
maintained throughout the six week study period (week 4:
12.362 mU/ml, P=0.09; week 6: 14.4 mU/ml, P=0.007).
Hyperinsulinemia occurred despite absolutely no change in fasting
plasma glucose (week 0: 93.861.9 vs. week 2: 94.361.3; P=0.88,
week 4: 9361.4; P=0.77, week 6: 94.461.3 mg/dl; P=0.84,
Fig. 2B). But, FFA were elevated by week 2 (week 0: 0.5560.05 vs.
week 2: 0.6660.05 mM, P=0.04, Fig. 2C). This increase was
maintained through week 4 (P=0.03). At week 6, fasting FFAs
further increased by 35% (week 6: 0.7460.05 mM, P,0.001).
Evening and nocturnal glucose and FFAs
At weeks 0 and 6, 10 additional samples of glucose and FFAs
were obtained within two time intervals (6–8 PM, 2–4 AM). There
was no change in the plasma glucose at the 6–8 pm interval before
Figure 1. Weekly changes in body weight and body composi-
tion. (A) Body weight increased by week 2 and remained elevated
throughout the six-week hypercaloric high-fat feeding period. (B)
Visceral (white bar) and subcutaneous (black bar) adipose tissue
calculated as area percent of total tissue. *P,.05 vs. week0; **P,.01 vs.
week 0; ***P,.001 vs. week 0.
doi:10.1371/journal.pone.0018134.g001
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95.563.5 mg/dl, P=NS, Fig. 3A). Also, there was no change in
the plasma glucose in the time interval 2–4 AM (week 0: 92.861.7
vs. week 6: 94.461.3 mg/dl, P=NS). In contrast to glycemia, a
160% increase in evening FFAs was observed with fat feeding
(week 0: 0.2360.03 vs. week 6: 0.660.03 mM, P,0.001, Fig. 3B).
A 68% increase in the nocturnal FFAs was observed with fat
feeding (week 0: 0.3760.03 vs. week 6: 0.6260.03 mM, P,.001).
Insulin Sensitivity (SI)
The high fat diet caused SI to drop 22% by week 2 (week 0:
3.760.3 vs. week 2: 2.960.3 (mu/l)‘-1.min‘-1, P=0.021, Fig. 4A).
By week 4, SI was further reduced by 41% (P,0.001). At week 6,
insulin sensitivity was reduced by 50% when compared to week 0
(week 6: 1.960.3 (mu/l)‘-1.min‘-1, P,0.001).
MCR of Insulin
We observed a trend for a decrease in MCR of insulin by week
2 (week 0: 8.961 vs week 2: 7.9460.9 ml/kg/min, P=NS, Fig.
4C). By week 4, the decrease became significant and more
pronounced (week 4: 6.860.9 ml/kg/min, P=0.016). Fat feeding
caused a 33% decrease in MCR of insulin by week 6 (P=0.001).
Glucose Tolerance (Kg) and Disposition Index (DI)
Glucose tolerance was not altered over the period of six weeks
(P=NS, Fig. 5A). Additionally, DI remained constant over the
study period (week 0: 1912.26303, week 2: 1820.16348, week 4:
1875.66348, week 6: 1871.76348, P=NS, Fig. 5B). The
hyperbola on Figure 6 was generated from extrapolated values
of insulin secretion (AIRg) based on observed value of DI for week
0 and varying SI in the range from1 to 7. All subsequent bi-weekly
observations of SI and AIRg are represented by a graphical
symbol with the respective SE (Fig. 6). Figure 6 shows that none of
the bi-weekly observations significantly deviate from the hyperbola
computed from the observed value of DI at week 0. Thus, this
figure illustrates the complete hyperinsulinemic compensation for
insulin resistance induced by fat feeding (Fig. 6).
Figure 2. Observed fasting plasma insulin, glucose and FFAs.
Fasting levels of (A) insulin, (B) glucose, and (C) FFA before and after fat
feeding. *P,.05 vs. week0; **P,.01 vs. week 0; ***P,.001 vs. week 0.
doi:10.1371/journal.pone.0018134.g002
Figure 3. Glucose and FFA plasma levels at three time periods
during 24-hr before and after fat feeding. (A) Plasma glucose and
(B) plasma FFAs during 2–4 AM (hash bars), 8–8:30 AM (black bars), and
6–8 PM (white bars). *P,.05 vs. week0; **P,.01 vs. week 0; ***P,.001
vs. week 0.
doi:10.1371/journal.pone.0018134.g003
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Fasting FFAs were significantly correlated with change in fasting
insulin (r=0.37, P,0.05, Fig. 7).
Discussion
The goal of this study was to examine the possibility that early-
week changes in plasma glucose, FFAs, or both, are nutrient
signals that lead to hyperinsulinemic compensation. To test our
hypothesis, we utilized a model of canine obesity based on feeding
dogs a hypercaloric, high-fat diet to induce the development of
insulin resistance. The ensuing insulin resistance was countered
with the onset of hyperinsulinemic compensation. The result of
our observation was that the DI remained unchanged (Fig. 6).
Thus, this study supports previous studies from our lab and others,
demonstrating almost perfect maintenance of glucose tolerance in
the face of insulin resistance, sustained by complete compensation
for the ensuing resistance and constant Dl [18,5].
Here we focused on examining the possible nutrient signals for
the compensation. One potential candidate signal is the change in
the plasma glucose level that develops as a consequence of reduced
insulin sensitivity, which leads to diminished capability of cells to
metabolize glucose, and a subsequent rise of glucose levels in the
circulation. However, we found absolutely no change in morning
fasting glucose over the period of six weeks (Fig. 2B) and no
measurable changes in plasma glucose levels at two additional time
periods (6–8 pm and 2–4 am) (Fig. 3A). This was not surprising
finding since our previous studies have shown that dietary
interventions in the canine model result in no changes in EGP
and only mild peripheral insulin resistance, two factors that may
lead to elevated plasma glucose [16,12,19]. Thus, the fact that
basal EGP is unchanged with high-fat feeding combined with
relatively unchanged peripheral disposal may explain the fact that
fasting, 6–8 pm, and 2–4 am plasma glucose levels remained
unchanged (Fig. 2B, Fig. 3A). These findings are in concordance
with previous studies in which dog or human populations in the
pre-diabetic state were able to maintain normoglycemia despite
the onset of insulin resistance [5,12,8,9].
Another possible signal for hyperinsulinemic compensation can
be the change in plasma FFA levels. Our group and others have
shown significant changes in the nocturnal FFA levels in the
insulin resistant or diabetic state [20,13], leading to the hypothesis
that perhaps the change in plasma FFA levels, and not plasma
glucose, may be the signal for hyperinsulinemic compensation
[21,22]. In this study we focused on the possibility that earlier-
week changes in plasma FFAs may be the signal for hyperinsu-
linemic compensation. Our study confirmed that evening and
nocturnal FFAs were significantly elevated by week 6 when
compared to the observations at the same time interval at week 0.
At week 6, evening FFAs showed a 160% increase (P,0.001),
while nocturnal FFAs had a 68% increase (P,0.001) when
compared to week 0. We did not conduct bi-weekly sampling of
evening and nocturnal FFAs because the night time sampling
protocol can be disruptive to the animal’s daily routine. Disrupting
the rest/sleep pattern may lead to additional insulin resistance,
which may be associated with other factors, such as sleep
deprivation, and not necessarily caused by increased nutrient flow
[23]. Since the rise in nocturnal FFAs is a slow process, we
assumed that the subsequent increase in nocturnal FFAs would
also be a gradual process. Therefore, we would be able to measure
partial changes in plasma FFAs by collecting the fasting samples
early in the morning. Our study identified an earlier-week rise in
fasting FFAs as another potential signal. We observed a statistically
significant rise in fasting FFAs at week 2 (20% increase, P=0.04)
that was sustained throughout the study period (Fig. 2C). At week
6, plasma FFAs were increased by 35% (P,0.001).
There may be three explanations for this rise in plasma FFA
levels. First, since the diet was rich in fat (53% of the total calories
were from fat), it is reasonable to postulate that the higher
availability of FFAs may lead to the rise in plasma FFAs. Second,
the hypercaloric, high-fat diet led to a 23% rise in total adipose
tissue by week 6, which could lead to elevated FFA levels. It has
been shown that the increased size of the adipose tissue depot leads
to an elevated lipolysis rate, especially in the visceral adipose tissue
(VAT) that drains directly into the portal vein [24,25,26,27]; thus,
Figure 4. Weekly estimates of insulin sensitivity, insulin
secretion and whole-body insulin clearance. (A) SI, (B) AIRg, and
(C) MCR of insulin. *P,.05 vs. week 0; **P,.01 vs. week 0; ***P,.001 vs
week 0.
doi:10.1371/journal.pone.0018134.g004
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the rise in FFA levels. Third, it is possible that the increase in
plasma FFA levels is due to increased sympathetic nervous system
(SNS) activity. SNS activity is markedly increased in the insulin
resistant state such as obesity and Type 2 diabetes [28].
Examination of the profiles of the weekly changes in fasting
insulin and early-morning fasting FFAs in our study exhibited
remarkable similarities (Fig. 2A, C). The bi-weekly average rate of
change in fasting insulin was very similar to the rate of change in
fasting FFA. In contrast, this pattern was missing when fasting
glucose was considered (Fig. 2B). Statistical analysis of the data
revealed a significant correlation between weekly changes in
fasting insulin and changes in FFAs (Fig. 7B, r=0.38,
P,0.05).The previously noted strong visual similarities between
weekly changes in insulin and early morning FFAs seem not to be
confirmed with the moderately statistically significant correlation.
One possibility for the lack of a much stronger correlation could be
due to variability in both insulin and FFAs. It is well established
that both insulin and FFAs are released in a pulsatile manner [29].
Therefore, the high variability may be a consequence of the fact
that our measurements may reflect both peaks and troughs of
insulin and FFA release. Another possibility is that the early
morning plasma FFAs are not appropriate surrogates for nocturnal
plasma FFA levels. From figure 3B it is evident that the increase of
65% in nocturnal plasma FFA level at week 6 is higher than the
change of 35% in the early morning FFA levels. Thus, we believe
that high variability in insulin and FFA, which is more than likely
attributed to the pulsatile release of these substrates combined with
the attenuated change in early morning plasma FFA levels,
resulted in a moderate correlation. Hence, we maintain that the
increase in nocturnal plasma FFAs observed during the develop-
ment of obesity may represent a signal for hyperinsulinemic
compensation.
Elevated plasma FFA levels have previously been shown to be
related to insulin resistance [30]. It has also been shown that an
increase in FFAs leads to alterations in insulin clearance [31].
Additionally, we have shown that the fat-fed canine model of
obesity has a decreased first-pass hepatic extraction [32], which
Figure 5. Weekly estimates of glucose tolerance and disposition index. (A) Glucose tolerance (Kg), (B) and disposition index (DI) over the 6
weeks of hypercaloric high-fat feeding period. *P,.05 vs. week 0; **P,.01 vs. week 0; ***P,.001 vs. week 0.
doi:10.1371/journal.pone.0018134.g005
Figure 6. Consistency of the hyperbolic relationship (DI)
between insulin sensitivity and insulin secretion. Solid black
hyperbolic curve= average DI value for week 0; black solid square =
average DI for week 0; open square = average DI for week 2; black solid
triangle = average DI for week 4; open triangle = average DI for week
6. The hyperbola represents the curve on which the animals would have
to remain to maintain a constant DI (DI=AIRg.SI=constant) and it is
calculated as extrapolation of the average DI for week 0 over a range of
insulin sensitivities.
doi:10.1371/journal.pone.0018134.g006
Figure 7. Spearman’s rank correlation between fasting insulin
and fasting FFA.
doi:10.1371/journal.pone.0018134.g007
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the results from our study, which show that by week 4 of
hypercaloric, high-fat feeding MCR of insulin was significantly
reduced by 23% (P=0.016). By week 6, MCR of insulin was
reduced by 33% (P=0.001). Therefore, it is possible that the
observed early-week increase in nocturnal FFAs will lead to
increased plasma insulin levels by altering the metabolism of
insulin in the liver. Interestingly, many studies fail to identify the
changes in insulin clearance as a physiologic adaptation that in
combination with increased insulin secretion results in elevated
plasma insulin levels. Another possibility is that the growth of the
adipose visceral depot leads to an elevation in lipolysis and
elevated FFAs levels in the portal vein. Increased influx of FFAs
are well correlated with hepatic insulin resistance [33]. During a
meal, the pancreas senses the rapid rise in plasma nutrient levels
and releases a burst of insulin, which directly or indirectly result in
complete suppression of EGP. The onset of obesity associated with
the rise in plasma FFA levels and hepatic insulin resistance may
prevent complete suppression from occurring[16]. Due to the
continuous endogenous and exogenous supply of glucose, plasma
glucose levels would remain elevated with the pancreas producing
more insulin to renormalize glucose levels. Longitudinally, this
anomaly might lead to an increase of beta cell mass and
consequent hyperinsulinemia.
Previous studies suggest an interaction between glucose and free
fatty acids with normal beta cell function, which raises the
possibility that imbalances between the two fuels in vivo can have
pathological consequences, such as impaired glucose-stimulated
insulin secretion (GSIS)[34]. Nolan and colleagues hypothesized
three potential mechanisms through which FFAs in conjunction
with glucose may lead to amplification of GSIS [21]. Two of the
pathways implicate beta cell intercellular metabolism of FFAs,
whereas, the third is related to membrane free fatty acid receptor
(FFAR) activation. Regardless, a change in plasma FFAs can be
detected by the b-cell through the G-protein-coupled receptor
GPR40/FFAR1 without any changes in plasma glucose levels and
may lead to increased secretion of insulin [20]. Thus, in the
absence of plasma glucose changes, which were observed in our
study, FFAs can act as the signal leading to increased GSIS.
In summary, six weeks of a hypercaloric, high-fat diet induced
severe insulin resistance in the canine model. Even in the face of
extreme insulin resistance, DI remained unchanged due to
complete hyperinsulinemic compensation. Here we offer addition-
al evidence of the temporal sequence for hyperinsulinemic
compensation. Our data strongly suggests that the early
evolution of obesity-induced elevation of nocturnal FFA
may directly modulate GSIS in the pancreas and/or
indirectly reduce hepatic insulin clearance, either
mechanism serving as a potential hyperinsulinemic
compensatory signal.
To effectively prevent the onset of diabetes, it is pertinent to
understand the early changes in the pre-diabetic state. Our results
indicate that in the case of complete hyperinsulinemic compen-
sation for insulin resistance there were no observable changes in
ambient plasma glucose. Therefore, it is plausible that when
glucose levels change, such as in impaired glucose tolerance (IGT),
some of the compensatory mechanisms may have been irreversibly
lost. Hence, screening early morning fasting FFA or insulin may be
an effective strategy in early detection of subject with high risk for
development of diabetes. However, due to the fact that currently
there are no available standards for measuring both insulin and
FFA we believe that our proposed screening strategy may be a
viable option in the future.
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